Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China: a Retrospective Database-based Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart Failure
- Sponsor
- Peking University First Hospital
- Enrollment
- 22500
- Locations
- 1
- Primary Endpoint
- Number of GDMT drugs (classified as RAASi (including ARNI), beta blockers, MRA and SGLT2i)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This is a retrospective, researcher-initiated, database-based study that will retrospectively observe the treatment and medication patterns of about 22,500 patients with heart failure from 25 heart failure centers and 25 non-heart failure centers in the database of heart failure center. The proportion of patients with heart failure treatment drugs reaching the target dose recommended in the guidelines and discontinuation rate will be observed at 1 month, 3 months and 12 months follow up time point. The purpose of this study is to illustrate the current HF treatment status in HF center hospitals and non-HF center hospitals, which may provide insights for improving the clinical practice of heart failure treatment in China, and promote the standardization of heart failure treatment in China.
Investigators
Yong Huo
Prof
Peking University First Hospital
Eligibility Criteria
Inclusion Criteria
- •An index HF diagnosis date in the records
- •Age ≥ 18 years old at initial diagnosis date
- •HF patients baseline characteristic record
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Number of GDMT drugs (classified as RAASi (including ARNI), beta blockers, MRA and SGLT2i)
Time Frame: At baseline and at 1 month, 3 month, 12 month follow-up time point
Numbers of GDMT drugs of HF patients stratified by HF ejection fraction and by HF Center and Non-HF Center
Use rates of GDMT drugs
Time Frame: At baseline and at 1 month, 3 month, 12 month follow-up time point
The percentage of patients using each GDMT drug，stratified by HF ejection fraction and by HF Center and Non-HF Center
Secondary Outcomes
- Discontinuation rate of each GDMT drug(at 1 month, 3 month, 12 month follow-up time point)
- The proportion of patients using 2 types of GDMT drugs(At baseline and at 1 month, 3 month, 12 month follow-up time point)
- The proportion of patients using 3 types of GDMT drugs(At baseline and at 1 month, 3 month, 12 month follow-up time point)
- The proportion of patients using 4 types of GDMT drugs(At baseline and at 1 month, 3 month, 12 month follow-up time point)
- The proportion of patients with each GDMT drug in the target dose(at 1 month, 3 month, 12 month follow-up time point)